Home  >  Research  >  Labs  >  Cancer Program  >  CANCER EPIGENETICS

RESEARCH OVERVIEW

The Cancer Epigenetics Laboratory is a multidisciplinary group that focuses on the development of novel approaches to target cancers that are currently refractory to treatment and associated to poor outcome, such as triple negative breast cancers and serious ovarian cancers. At present, there are no targeted approaches to combat these tumors, with chemotherapy and radiation the only treatment options. The laboratory generates novel functionalised molecules able to specifically target these tumors with minimal toxicity to normal cells. Our emphasis is in advanced stage metastatic tumors, which quasi invariably develop resistance. Ultimately we wish to revert the behaviour of metastatic cells by sensitising these treatment resistant tumors to chemotherapy regimes.

The lab deploys state-of-the art precision medicine tools to specifically re-engineer the genome and the epigenome of cancer cells, to restore mitotically hereditable (normal-like) features. Tools currently employed by the lab members include artificial genome engineering proteins (e.g made of zinc fingers, CRISPR/dCas9 backbones) attached to a library of effector domains for epigenomic editing.

The lab has patented and developed interference peptide technology, small synthetic and functionalised cell-penetrating peptides programmed to inhibit oncogenic transcription factors overexpressed in metastatic cells. By blocking or inhibiting essential protein-protein interactions we promote potent and selective apoptosis in metastatic breast cancer cells while sensitizing these tumors to chemotherapy regimes. Lastly, we collaborate with nanotechnology investigators (S. Iyer, UWA & Leaf Huang, UNC) to encapsulate these agents using targeted nanoparticles.

Associate Professor Pilar Blancafort

Associate Professor Pilar Blancafort

Cancer Epigenetics (Program Head - Cancer)

Read more

LATEST NEWS

WA researchers excel in nationally competitive grants

Eight (8) Federal government grants awarded to the Harry Perkins Institute of Medical Research Two of Australia’s most significant research grants, given only to the nation’s highest performing researchers, have been awarded to Harry Perkins Institute of Medical Research scientists. Associate Director of the Institute, The University of Western Australia’s…

Read More

New discovery for treatment of primary liver cancer shows promise

A study using preclinical models has discovered a drug combination with the potential to treat one of the most fatal and globally widespread cancers, a type of primary liver cancer called hepatocellular carcinoma (HCC). The collaborative research team found the drug combination reverses the symptoms of nonalcoholic steatohepatitis (NASH) and,…

Read More
Dr Ankur Sharma in front of MRI image at Harry Perkins Institute of Medical Research

New liver cancer blood test gets $2.5m research funding boost

Predicting relapse for one of the world's deadliest cancers. Perth cancer researchers are on track to improve the outcomes of patients with the most common type of primary liver cancer. Hepatocellular carcinoma (HCC) is one of the most aggressive cancer types. Patients typically suffer a high rate of treatment failures.…

Read More

I'M LOOKING FOR

RESEARCH PROJECTS

TEAM MEMBERS

PUBLICATIONS